Oral News and Research

RSS

Next-generation oral SERD therapy lowers the risk of breast cancer recurrence

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1-3) hormone receptor (HR)-positive, HER2-negative breast cancer, significantly lowered the risk of the disease returning when compared with standard hormone therapies long considered the backbone of treatment.

10 Dec 2025

Triaptosis could be a promising strategy in the fight against cancer

Cancer remains one of the most critical global public health challenges, exerting profound social, economic, and clinical burdens while limiting gains in human life expectancy.

10 Dec 2025

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

10 Dec 2025

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

Researchers profiled a terminally sterilized probiotic-fermented MFH beverage and identified aporphine alkaloids and flavonoids with favorable predicted ADMET properties. Integrated network pharmacology, molecular docking, and 100-ns MD simulations suggest multi-target engagement of metabolic-inflammatory pathways relevant to obesity and type 2 diabetes.

9 Dec 2025

Study uncovers how the body's bile acids bind to block C. diff's most dangerous toxin

In a major step towards a precision therapy for Clostridioides difficile (C. diff) infection, researchers at The Hospital for Sick Children (SickKids) have uncovered how the body's bile acids bind to block C. diff's most dangerous toxin.

9 Dec 2025

Lubiprostone shows signs of slowing kidney function decline in chronic kidney disease

In adults with stage IIIb–IV chronic kidney disease, the constipation drug lubiprostone did not reduce gut-derived uremic toxins but preserved creatinine-based kidney function over 24 weeks. The benefit was linked to microbiome remodeling, increased polyamine production, and improved mitochondrial function rather than toxin lowering.

8 Dec 2025

Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, are associated with high rates of death unrelated to cancer relapse-primarily infection-and may be avoidable.

8 Dec 2025

New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma

Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an aggressive form of brain cancer, live longer.

8 Dec 2025

Blood sugar migration to saliva fuels cavity development in type 2 diabetes patients

Individuals with type 2 diabetes often have a higher incidence of tooth decay, but the underlying mechanisms remain unclear.

8 Dec 2025

Kiwifruit intake boosts vitamin C in skin and supports dermal structure

Study shows that increasing dietary vitamin C intake with kiwifruit raises vitamin C levels in both the dermis and epidermis through active transport from the bloodstream. Higher skin vitamin C levels were associated with increased skin density and epidermal cell proliferation, but not with improved UV protection or measurable increases in new collagen markers.

7 Dec 2025

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy.

7 Dec 2025

Calcium supplements do not prevent pre-eclampsia, large trials show no meaningful benefit

Despite long-standing recommendations, a major updated Cochrane review finds that calcium supplementation during pregnancy does not meaningfully reduce pre-eclampsia risk, prompting a rethink of how best to prevent hypertensive disorders in pregnancy.

7 Dec 2025

Quality improvement project dramatically boosts iron deficiency screening in pregnancy

Within a year of initiation, a multidisciplinary project to improve screening and treatment for iron deficiency in pregnancy resulted in a sixfold rise in screening rates for iron deficiency in pregnant patients, a 20-fold rise in the number of intravenous (IV) iron infusions, and a significant improvement in median hemoglobin levels.

7 Dec 2025

Study finds no specific harms linked to hydroxyurea exposure during pregnancy

Taking the sickle cell drug hydroxyurea during or shortly before pregnancy does not appear to cause specific issues in newborns, according to the first prospective study of pregnancies involving hydroxyurea exposure.

7 Dec 2025

$New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer$

New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, investigators found that a single dose of the alpha-emitting radionuclide 211At (astatine) was both well-tolerated and effective, achieving disease control without molecularly targeted drugs.

5 Dec 2025

New combination treatment helps people with recurring grade 3 astrocytoma, trial shows

5 Dec 2025

Research examines oral health benefits of toothbrush choice and brushing duration

Real progress in oral health doesn't come from expensive gadgets, but from better daily habits. That is the conclusion of dentist- periodontist Tim Thomassen in his dissertation Oral Disease Prevention, which he will defend on 12 December at the University of Amsterdam.

5 Dec 2025

First new fibromyalgia drug in 15 years, Tonmya (cyclobenzaprine HCl) gains FDA approval and hits pharmacy shelves

In a milestone moment for chronic pain management, Tonix Pharmaceuticals announced on August 15, 2025, that its novel sublingual therapy Tonmya has received approval from the U.S. Food and Drug Administration (FDA) - marking the first new drug for Fibromyalgia in more than 15 years.

From Hanson Wade Group - Non-Opioid Pain Therapeutics Summit 5 Dec 2025

Long-acting HIV treatment could improve outcomes for breastfeeding women

Sujata Tewari, BA, previously of the Medical Practice Evaluation Center (MPEC) at Massachusetts General Hospital, and Andrea L. Ciaranello, MD, MPH, of the MPEC and Department of Medicine at Massachusetts General Hospital, are the lead and senior authors of a paper published in the Journal of Infectious Diseases, “Long-acting antiretroviral therapy for breastfeeding women with HIV experiencing barriers to adherence in Zimbabwe: Modeling clinical impact and cost-effectiveness.

4 Dec 2025

Cystic fibrosis patients on triple-drug therapy can safely reduce daily lung treatments

A new multi-site study led by researchers at CU Anschutz shows that people with cystic fibrosis (CF) who start the triple-drug therapy elexacaftor/tezacaftor/ivacaftor (ETI) can safely reduce many of their daily lung treatments while maintaining good health for years.

4 Dec 2025

Oral News and Research

Next-generation oral SERD therapy lowers the risk of breast cancer recurrence

Triaptosis could be a promising strategy in the fight against cancer

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

Study uncovers how the body's bile acids bind to block C. diff's most dangerous toxin

Lubiprostone shows signs of slowing kidney function decline in chronic kidney disease

Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause

New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma

Blood sugar migration to saliva fuels cavity development in type 2 diabetes patients

Kiwifruit intake boosts vitamin C in skin and supports dermal structure

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

Calcium supplements do not prevent pre-eclampsia, large trials show no meaningful benefit

Quality improvement project dramatically boosts iron deficiency screening in pregnancy

Study finds no specific harms linked to hydroxyurea exposure during pregnancy

New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer

New combination treatment helps people with recurring grade 3 astrocytoma, trial shows

Research examines oral health benefits of toothbrush choice and brushing duration

First new fibromyalgia drug in 15 years, Tonmya (cyclobenzaprine HCl) gains FDA approval and hits pharmacy shelves

Long-acting HIV treatment could improve outcomes for breastfeeding women

Cystic fibrosis patients on triple-drug therapy can safely reduce daily lung treatments

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News